0000000000372437

AUTHOR

Renata Ciccarelli

0000-0003-1412-738x

showing 9 related works from this author

Adipose Stromal/Stem Cell-Derived Extracellular Vesicles: Potential Next-Generation Anti-Obesity Agents

2022

Over the last decade, several compounds have been identified for the treatment of obesity. However, due to the complexity of the disease, many pharmacological interventions have raised concerns about their efficacy and safety. Therefore, it is important to discover new factors involved in the induction/progression of obesity. Adipose stromal/stem cells (ASCs), which are mostly isolated from subcutaneous adipose tissue, are the primary cells contributing to the expansion of fat mass. Like other cells, ASCs release nanoparticles known as extracellular vesicles (EVs), which are being actively studied for their potential applications in a variety of diseases. Here, we focused on the importance …

obesityAdipogenesisQH301-705.5Organic ChemistrySubcutaneous FatMesenchymal Stem CellsGeneral Medicinemetabolic disease/syndromeSettore BIO/09 - FisiologiaCatalysisComputer Science Applicationsadipose tissueInorganic ChemistryChemistrySettore BIO/14 - Farmacologiaadipose stromal/stem cells (ASCs)Adipose stromal/stem cells (ASCs) Adipose tissue Extracellular vesicles Metabolic disease/syndrome ObesityHomeostasisHumansPhysical and Theoretical ChemistryBiology (General)extracellular vesiclesMolecular BiologyQD1-999SpectroscopyInternational Journal of Molecular Sciences
researchProduct

Modulation of the TGF-β1-induced epithelial to mesenchymal transition (EMT) mediated by P1 and P2 purine receptors in MDCK cells

2017

Epithelial to mesenchymal transition (EMT) occurs during embryogenesis or under pathological conditions such as hypoxia, injury, chronic inflammation, or tissue fibrosis. In renal tubular epithelial cells (MDCK), TGF-β1 induces EMT by reducing or increasing epithelial or mesenchymal marker expression, respectively. In this study, we confirmed that the cAMP analogues, 8-CPT-cAMP or N6-Ph-cAMP, inhibited the TGF-β1-driven overexpression of the mesenchymal markers ZEB-1, Slug, Fibronectin, and α-SMA. Furthermore, we showed that A1, A2A, P2Y1, P2Y11, and P2X7 purine receptor agonists modulated the TGF-β1-induced EMT through the involvement of PKA and/or MAPK/ERK signaling. The stimulation o…

0301 basic medicineMAPK/ERK pathwayMadin Darby canine kidney cellEpithelial-Mesenchymal TransitionFibrosiCellTransforming growth factor β1InflammationStimulationBiologyEpithelial to mesenchymal transition; Fibrosis; Madin Darby canine kidney cells; P1/P2 purinergic receptors; Transforming growth factor β1; Molecular Biology; Cellular and Molecular Neuroscience; Cell BiologyTransforming Growth Factor beta103 medical and health sciencesCellular and Molecular Neuroscience0302 clinical medicineDogsmedicineAnimalsEpithelial–mesenchymal transitionReceptorMolecular BiologyEpithelial to mesenchymal transitionP1/P2 purinergic receptorReceptors Purinergic P2Mesenchymal stem cellReceptors Purinergic P1Cell BiologyMadin Darby canine kidney cellsFibrosisCell biologyFibronectin030104 developmental biologymedicine.anatomical_structure030220 oncology & carcinogenesisbiology.proteinP1/P2 purinergic receptorsOriginal ArticleTransforming growth factor β1medicine.symptomTransforming growth factor
researchProduct

The Guanine-Based Purinergic System: The Tale of An Orphan Neuromodulation.

2016

Guanine-based purines (GBPs) have been recently proposed to be not only metabolic agents but also extracellular signaling molecules that regulate important functions in the central nervous system. In such way, GBPs-mediated neuroprotection, behavioral responses and neuronal plasticity have been broadly described in the literature. However, while a number of these functions (i.e., GBPs neurothophic effects) have been well-established, the molecular mechanisms behind these GBPs-dependent effects are still unknown. Furthermore, no plasma membrane receptors for GBPs have been described so far, thus GBPs are still considered orphan neuromodulators. Interestingly, an intricate and controversial f…

0301 basic medicineCell signalingAdenosineAdenosinaguanine-based purines; guanosine; neuroprotectionReviewBiologySettore BIO/09 - FisiologiaNeuroprotection03 medical and health sciences0302 clinical medicineguanine-based purinespurinergic receptorsmedicineGuanosine triphosphatasePharmacology (medical)ReceptorPharmacologyTrifosfat de guanosinasynaptic plasticityPurinergic receptorAdenosine; Guanine-based purines; Guanosine; Neuroprotection; Purinergic receptors; Synaptic plasticity; Pharmacology; Pharmacology (medical)Adenosine receptorAdenosineNeuromodulation (medicine)guanosine030104 developmental biologyBiochemistryPurinesadenosineSynaptic plasticityneuroprotectionNeurosciencePurinergic receptor030217 neurology & neurosurgeryGuanine-based purinemedicine.drugFrontiers in pharmacology
researchProduct

Guanine inhibits the growth of human glioma and melanoma cell lines by interacting with GPR23

2022

Guanine-based purines (GBPs) exert numerous biological effects at the central nervous system through putative membrane receptors, the existence of which is still elusive. To shed light on this question, we screened orphan and poorly characterized G protein-coupled receptors (GPRs), selecting those that showed a high purinoreceptor similarity and were expressed in glioma cells, where GBPs exerted a powerful antiproliferative effect. Of the GPRs chosen, only the silencing of GPR23, also known as lysophosphatidic acid (LPA) 4 receptor, counteracted GBP-induced growth inhibition in U87 cells. Guanine (GUA) was the most potent compound behind the GPR23-mediated effect, acting as the endpoint eff…

Pharmacologyantiproliferative effectspurine nucleoside phosphorylase (PNP)G protein-coupled receptor 23 (GPR23)glioma cell linesSettore BIO/14 - Farmacologiaguanine-based purines (GBPs)Pharmacology (medical)melanoma cell linesMelanomaguanine (GUA)lysophosphatidic acid (LPA)
researchProduct

Altered gastrointestinal motility in an animal model of Lesch-Nyhan disease.

2018

Mutations in the HGPRT1 gene, which encodes hypoxanthine-guanine phosphoribosyltransferase (HGprt), housekeeping enzyme responsible for recycling purines, lead to Lesch-Nyhan disease (LND). Clinical expression of LND indicates that HGprt deficiency has adverse effects on gastrointestinal motility. Therefore, we aimed to evaluate intestinal motility in HGprt knockout mice (HGprt(−)). Spontaneous and neurally evoked mechanical activity was recorded in vitro as changes in isometric tension in circular muscle strips of distal colon. HGprt(−) tissues showed a lower in amplitude spontaneous activity and atropine-sensitivity neural contraction compared to control mice. The responses to carbachol a…

0301 basic medicineAtropineMaleHypoxanthine PhosphoribosyltransferaseLesch-Nyhan SyndromeDopaminemedicine.disease_causeSettore BIO/09 - FisiologiaLesch-NyhanMice0302 clinical medicineEnzyme InhibitorsEvoked PotentialsMyenteric plexusHGprt deficient miceNeurotransmitter AgentsBrainNG-Nitroarginine Methyl EsterKnockout mouseCytokinesAcetylcholinemedicine.drugmedicine.medical_specialtyCarbacholTyrosine 3-MonooxygenaseColonMotilityMice TransgenicIn Vitro TechniquesEndocrine and Autonomic SystemArticleContractility03 medical and health sciencesCellular and Molecular NeuroscienceDopamineInternal medicinemedicineAnimalsCytokineEndocrine and Autonomic Systemsbusiness.industryMuscle SmoothBenzazepinesMice Inbred C57BLDisease Models Animal030104 developmental biologyEndocrinologyGene Expression RegulationHGprt enzymeFaceOxidative streCarbacholNeurology (clinical)Lipid PeroxidationbusinessGastrointestinal MotilityReactive Oxygen Species030217 neurology & neurosurgeryOxidative stressAutonomic neuroscience : basicclinical
researchProduct

Guanosine Protects Glial Cells Against 6-Hydroxydopamine Toxicity

2014

Increasing body of evidence indicates that neuron-neuroglia interaction may play a key role in determining the progression of neurodegenerative diseases including Parkinson’s disease (PD), a chronic pathological condition characterized by selective loss of dopaminergic (DA) neurons in the substantia nigra. We have previously reported that guanosine (GUO) antagonizes MPP+-induced cytotoxicity in neuroblastoma cells and exerts neuroprotective effects against 6-hydroxydopamine (6-OHDA) and beta-amyloid-induced apoptosis of SH-SY5Y cells. In the present study we demonstrate that GUO protected C6 glioma cells, taken as a model system for astrocytes, from 6-OHDA-induced neurotoxicity. We show tha…

HydroxydopaminebiologyChemistryNeurodegenerationNeurotoxicitySubstantia nigraNucleoside transporterPharmacologymedicine.diseaseNeuroprotectionNeurotrophic factorsbiology.proteinmedicinePI3K/AKT/mTOR pathway
researchProduct

Uncovering the Signaling Pathway behind Extracellular Guanine-Induced Activation of NO System: New Perspectives in Memory-Related Disorders

2018

Mounting evidence suggests that the guanine-based purines stand out as key player in cell metabolism and in several models of neurodegenerative disorders, such as Parkinson's and Alzheimer's diseases. Guanosine (GUO) and guanine (GUA) are extracellular signaling molecules derived from the breakdown of the correspondent nucleotide, GTP, and their intracellular and extracellular levels are regulated by the fine-tuned activity of two major enzymes, purine nucleoside phosphorylase (PNP) and guanine deaminase (GDA). Noteworthy, GUO and GUA, seem to play opposite roles in the modulation of cognitive functions, such as learning and memory. Indeed GUO, despite exerting neuroprotective, anti-apoptot…

0301 basic medicineMAPK/ERK pathwayCell signalingGuanineGuanosine03 medical and health scienceschemistry.chemical_compoundGuanine deaminase0302 clinical medicineCGMP; ERK; Guanine; L-NAME; Nitric oxide; SH-SY5Y cell line; Pharmacology; Pharmacology (medical)L-NAMEnitric oxideExtracellularguaninePharmacology (medical)Original ResearchPharmacologyChemistrylcsh:RM1-950Cell biologycGMPERKlcsh:Therapeutics. Pharmacology030104 developmental biologySignal transductionSH-SY5Y cell line030217 neurology & neurosurgeryIntracellularFrontiers in Pharmacology
researchProduct

Investigating the Role of Guanosine on Human Neuroblastoma Cell Differentiation and the Underlying Molecular Mechanisms

2021

Neuroblastoma arises from neural crest cell precursors failing to complete the process of differentiation. Thus, agents helping tumor cells to differentiate into normal cells can represent a valid therapeutic strategy. Here, we evaluated whether guanosine (GUO), a natural purine nucleoside, which is able to induce differentiation of many cell types, may cause the differentiation of human neuroblastoma SH-SY5Y cells and the molecular mechanisms involved. We found that GUO, added to the cell culture medium, promoted neuron-like cell differentiation in a time- and concentration-dependent manner. This effect was mainly due to an extracellular GUO action since nucleoside transporter inhibitors r…

NeuriteCellular differentiationGuanosinePurine nucleoside phosphorylaseRM1-950Nucleoside transporterSettore BIO/09 - Fisiologiachemistry.chemical_compoundneuroblastomaguanine guanosine guanylate cyclase heme oxygenase neuroblastoma protein kinase C purine nucleoside phosphorylase SH-SY5YdifferentiationNucleòsidsExtracellularPharmacology (medical)guaninePharmacologybiologyMarcadors tumoralsNucleosidesSH-SY5YdifferentiationBrief Research Reportheme oxygenasepurine nucleoside phosphorylaseCell biologyguanylate cyclaseguanosinechemistryCell cultureTumor markersSettore BIO/14 - Farmacologiabiology.proteinTherapeutics. PharmacologyNucleosideprotein kinase C
researchProduct

Guanosine-Mediated Anxiolytic-Like Effect: Interplay with Adenosine A1 and A2A Receptors

2020

Acute or chronic administration of guanosine (GUO) induces anxiolytic-like effects, for which the adenosine (ADO) system involvement has been postulated yet without a direct experimental evidence. Thus, we aimed to investigate whether adenosine receptors (ARs) are involved in the GUO-mediated anxiolytic-like effect, evaluated by three anxiety-related paradigms in rats. First, we confirmed that acute treatment with GUO exerts an anxiolytic-like effect. Subsequently, we investigated the effects of pretreatment with ADO or A1R (CPA, CCPA) or A2AR (CGS21680) agonists 10 min prior to GUO on a GUO-induced anxiolytic-like effect. All the combined treatments blocked the GUO anxiolytic-like effect, …

LightPharmacologyAnxietySettore BIO/09 - FisiologiaHippocampuslcsh:Chemistrychemistry.chemical_compound0302 clinical medicineReceptorlcsh:QH301-705.5Spectroscopycaffeine0303 health sciencesBehavior AnimalRGeneral MedicineDarkness3. Good healthComputer Science ApplicationsadenosineCCPA[SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]A<sub>1</sub>RCaffeineA1Rmedicine.drugReceptor Adenosine A2A1GuanosineCatalysisArticleInorganic Chemistry03 medical and health sciencesAmedicineAnimals[SDV.NEU] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]Physical and Theoretical ChemistryBinding site2AMolecular Biology030304 developmental biologyDose-Response Relationship DrugReceptor Adenosine A1behaviorOrganic ChemistryCell MembraneAntagonistAdenosineAdenosine receptorRatsguanosineA<sub>2A</sub>Rlcsh:Biology (General)lcsh:QD1-999chemistryA2AR030217 neurology & neurosurgery
researchProduct